News
Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world ...
Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback